Koumine (Gelsemium Alkaloid · Non-opioid Analgesic · Highly Toxic Reference)
| Compound | Koumine (Gelsemium elegans alkaloid; 19,20-Didehydrogelsevine analogue) |
| Class | Alkaloid — Indole (Gelsemium-type monoterpene indole alkaloid) |
| CAS | 1358-76-5 |
| Molecular formula | C₂₀H₂₂N₂O₂ |
| Primary sources | Gelsemium elegans (heartbreak grass), Gelsemium sempervirens (Carolina jasmine) |
| Plant part | Roots, stems, leaves |
| Claim strength | Emerging |
| Key applications | Non-opioid analgesic research; neuropathic pain; anxiety; informational-only |
| Buy from Herbuno | Informational reference — see HerbIQ Compound Index → |
Name origin: Koumine is named after the Chinese term for Gelsemium elegans (Gou Wen — "hook vine" or more idiomatically "heartbreak grass"), from which it is one of the primary alkaloid constituents. It belongs to the Gelsemium-type monoterpene indole alkaloid (MIA) class, sharing structural features with gelsemine and gelsevirine but with distinct pharmacological properties. Traditional use: Gelsemium elegans (heartbreak grass, Duan Chang Cao) has a documented history of use in Chinese folk medicine — and infamously in poisoning. The plant is used topically in TCM for pain, skin conditions, and as an insecticide, but oral administration is dangerous due to the narrow safety margin of its alkaloids. Gelsemium elegans poisoning has been used historically in China as a suicide and assassination method (hence the common name "heartbreak grass"). Research trajectory: Koumine is specifically interesting because it has demonstrated analgesic and anxiolytic activity at doses well below the toxic threshold — unlike gelsemine and gelsevirine, which have much narrower therapeutic indices. Research groups in China and France have characterised koumine as a potential non-opioid analgesic for neuropathic pain with a mechanism involving glycine receptor potentiation. Safety context: Gelsemium elegans is one of the most toxic plants used in Chinese folk medicine. Gelsemine, the major alkaloid, causes respiratory paralysis at modest doses. Koumine has better tolerability but the parent plant's toxicity means any Gelsemium preparation carries significant poisoning risk without pharmaceutical-grade isolation and dosing. Not a supplement ingredient.
Research Profile of Koumine
Non-opioid analgesic mechanism: Koumine potentiates glycine receptor (GlyR) function — enhancing inhibitory glycinergic neurotransmission in the spinal cord dorsal horn, which is the primary gate for nociceptive signal transmission. This mechanism is analogous to proposed mechanisms for cannabinoids and some alpha-2 agonists, but is distinct from opioid receptor engagement. In rodent neuropathic pain models (spinal nerve ligation, CCI), koumine at 0.5–4 mg/kg significantly reduces mechanical allodynia and thermal hyperalgesia without tolerance development over 14-day administration. Claim strength: Emerging.
Anxiolytic activity: Koumine reduces anxiety-related behaviour in elevated plus maze and open field test models without motor impairment at analgesic doses. The anxiolytic mechanism may involve glycine receptor modulation in limbic structures, or indirect effects via reduced pain-associated stress. Claim strength: Emerging.
Neuroinflammatory modulation: In spinal cord and DRG (dorsal root ganglion) preparations, koumine reduces microglial activation and pro-inflammatory cytokine expression following nerve injury, suggesting a neuroimmune component to its analgesic activity alongside direct GlyR modulation. Claim strength: Emerging.
Therapeutic index vs. gelsemine: Koumine has a wider therapeutic index than gelsemine — the major Gelsemium alkaloid — allowing analgesic doses without the respiratory depression seen at toxic gelsemine concentrations. This relative safety advantage is the scientific rationale for koumine-specific research, though it remains inadequate for unregulated supplement use. Claim strength: Moderate (comparative pharmacology).
This compound is documented for research and formulator education purposes. For commercially available botanical ingredients, explore the HerbIQ Compound Index →
Safety and Research Context
Gelsemium elegans and G. sempervirens are acutely toxic plants. The alkaloid content (primarily gelsemine, koumine, gelsevirine) causes progressive CNS depression, respiratory paralysis, and death in overdose. Therapeutic use of Gelsemium preparations in homeopathy exists in heavily diluted form (30C, 200C dilutions where no active alkaloid molecules remain). These homeopathic preparations are not relevant to koumine pharmacology.
No pharmaceutical drug exists based on koumine. Research publications (predominantly from Chinese pharmacological institutes) have characterised koumine's analgesic mechanism; clinical translation has not commenced as of the HerbIQ knowledge reference date. The non-opioid analgesic mechanism is of significant pharmaceutical interest given the global opioid epidemic.
Formulators should note that Gelsemium sempervirens is listed in several countries as a plant subject to botanical regulatory controls due to its toxicity. Import, sale, and use of Gelsemium raw material or extracts is restricted in the EU and should be verified by jurisdiction before any commercial consideration.
This entry documents koumine's analgesic research significance within the HerbIQ Gelsemium alkaloid series, alongside gelsevirine, for formulator education on MIA alkaloid diversity.
Frequently Asked Questions — Koumine
What makes koumine interesting as a non-opioid analgesic candidate?
The glycine receptor potentiation mechanism of koumine is genuinely distinct from all current analgesic drug classes — it is not an opioid, NSAID, anticonvulsant, or SNRI. In neuropathic pain models, where opioids often lose efficacy, koumine maintains analgesic activity without tolerance development over 14 days in rodent studies. This mechanistic novelty, combined with a relatively better safety profile than gelsemine, makes it a pharmacologically interesting research compound for pain drug discovery.
How does koumine compare to gelsemine in toxicity?
Gelsemine is the principal Gelsemium alkaloid with the highest CNS and respiratory toxicity — LD₅₀ in rodents of approximately 9 mg/kg (IV). Koumine has a substantially higher LD₅₀ (estimated 3–5-fold greater), meaning it has a wider margin between analgesic doses (0.5–4 mg/kg in rodent models) and lethal doses. This relative safety advantage is the reason koumine is the focus of analgesic research rather than gelsemine, but the absolute toxicity still precludes supplement use.
Is Gelsemium used in any mainstream herbal medicine systems?
Gelsemium sempervirens appears in the American Eclectic medicine tradition (19th–early 20th century) for neuralgia, headache, and fever. It is still listed in the British Herbal Pharmacopoeia and used by some Western herbalists in very low doses for specific indications with professional supervision. Gelsemium elegans is used topically in Chinese medicine. Both applications are highly specialised due to the narrow safety margin — mainstream herbal practice avoids internal Gelsemium preparations.
What is the glycine receptor and why is it relevant to pain?
Glycine receptors (GlyR) are ligand-gated chloride channels mediating inhibitory neurotransmission in the spinal cord and brainstem. In the spinal dorsal horn, glycinergic interneurons normally inhibit pain signal transmission from peripheral nociceptors to brain. Nerve injury and chronic pain states are associated with reduced glycinergic inhibition (disinhibition), allowing pain signals to be amplified. Compounds that restore GlyR function — like koumine — could theoretically reverse this disinhibition and reduce neuropathic pain without opioid receptor engagement.
Related compounds: Gelsevirine, Strychnine, Brucine, Securinine
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery